Frequency Research Chart

Circulating tumor cells fell 75% one day after one session. After the full multimodal protocol, five liver lesions became one visible lesion and the largest changed from 12 mm to 9 mm.

Surgery, anti-angiogenesis therapy, infusions, medicines, and supplements were used too. The report cannot isolate a Rife effect or establish causation.

Researchers cataloged 1,524 modulation frequencies. Among 13 evaluable patients, one complete response, one partial response, and four periods of stable disease were reported.

Small, uncontrolled, mixed-cancer sample with an unusual biofeedback selection method. It was designed for feasibility, not efficacy.

Seven-day exposure reduced proliferation in a frequency- and tissue-specific pattern and altered selected gene expression in liver cancer cells.

Laboratory cell behavior does not establish safety, dose, or clinical benefit in people.

Fourteen patients had stable disease beyond six months. Median progression-free survival was 4.4 months and overall survival was 6.7 months; three partial and one near-complete response were recorded.

No control group, small cohort, and inventor or commercial conflicts. Randomized confirmation was explicitly needed.

No serious procedure adverse events were reported. Median overall survival was 11.3 months and exploratory objective response rate was 24.3%.

Uncontrolled, non-randomized, and confounded by concurrent standard treatments. Survival and response were exploratory endpoints.

With temozolomide, median progression-free survival was 6.7 versus 4.0 months and overall survival was 20.9 versus 16.0 months; both hazard ratios were 0.63.

The comparison was open-label, treatment required at least 18 hours per day, and 52% had mild-to-moderate skin toxicity under the arrays.

Adding fields to standard therapy increased median overall survival to 13.2 months from 9.9 months; hazard ratio 0.74, p=0.035.

Open-label device trial with local skin effects and manufacturer sponsorship; results apply to the tested device and treatment combination.

In intention-to-treat analysis, 12-month progression-free survival was 28.7% versus 17.3%, but the difference was not statistically significant (p=0.146).

The primary endpoint was not met. The positive progression-free result appeared only in a smaller evaluable subgroup and needs larger confirmation.

Across 14 pooled trials, healing was 79.7% with PEMF versus 64.3% with sham or control; risk ratio 1.22. Pain also improved in the pooled estimate.

Protocols varied and heterogeneity was substantial. Evidence was moderate for healing and pain but very low quality for faster healing time.

Response was 45.3% with active treatment versus 24.2% with control; remission was 38.3% versus 14.4%.

Results combine different protocols and showed moderate-to-high heterogeneity. They do not support a single universal healing frequency.